Critically ill pediatric patients frequently receive prolonged analgesia and sedation to provide pain relief and facilitate intensive care therapies. Iatrogenic withdrawal syndrome occurs when these drugs are stopped abruptly or weaned too rapidly. We investigated the validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) in children during weaning of analgesics and sedatives. Of 308 children initially supported on mechanical ventilation for acute respiratory failure, 126 (41%) from 21 centers (median age 1.6 years; interquartile range 0.6-7.7 years) were exposed to 5 or more days of opioids. Subjects were assessed for withdrawal symptoms with the WAT-1, an 11-item (12-point) scale, from the first day of weaning from analgesia/sedation until 72 h after the last opioid dose. A total of 836 daily WAT-1 assessments were completed, with a median (interquartile range) WAT-1 score of 2 (0-4) over 6 (3-9) days per subject. There were no significant differences in WAT-1 scores as a function of age. Factor analyses confirmed that motor-related symptoms and behavioral state accounted for the most variance in WAT-1 scores. Supporting construct validity, cumulative opioid exposures were greater [40.2 (19.7-83.4) vs 17.6 (14.6-39.7) mg/kg, P = .004], length of opioid treatment before weaning was longer [7 (6-11) vs 5 (5-8) days, P = .004], and length of weaning from opioids was longer [10 (6-14) vs 6 (3-9) days, P = .008] in subjects with WAT-1 scores of P3 compared to subjects with WAT-1 scores of <3. The WAT-1 shows good psychometric performance and generalizability when used to assess clinically important withdrawal symptoms in pediatric intensive care and general ward settings. Ó
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Introduction
Over 90% of infants and children supported on mechanical ventilation in the pediatric intensive care unit (PICU) setting receive some form of sedative therapy, most commonly various combinations of opioids and benzodiazepines [21, 25] . Although analgesia is required for pain management and sedation is often indicated in pediatric patients who are unable to understand the imperative nature of critical care instrumentation and immobility, analgesic and sedative use is associated with morbidity and mortality [5] .
Iatrogenic withdrawal can occur with the abrupt discontinuation or too rapid weaning of opioids and/or benzodiazepines. An estimated 10-34% of all PICU patients are at risk for iatrogenic withdrawal [16, 22] , and for those exposed to greater than 5 to 10 days of opioids and benzodiazepines, the risk is between 50% and 100% [12, 17] . Classic signs of opioid withdrawal include neurological excitability, gastrointestinal dysfunction, autonomic instability, and poor organization of sleep states [2] . Benzodiazepine withdrawal symptoms are similar but also include agitation, visual hallucinations, facial grimacing, small-amplitude choreic or choreoathetoid movements, and seizures [8, 24] .
The accurate assessment of iatrogenic opioid and benzodiazepine withdrawal is necessary for effective prevention and treatment but this remains challenging [15] . The lack of adequate measures of iatrogenic withdrawal and the need for such tools to guide pain and sedation therapy has been repeatedly highlighted [2, 11, 15, 18] . Several clinical assessment tools for critically ill children have been proposed [9, 10, 14] . The Withdrawal Assessment Tool-1 (WAT-1 [9], Fig. 1 ) was a significant improvement over previous withdrawal symptom assessment scales in that it has fewer items, each of which can be objectively measured. It is performed only twice a day, compared with the usual 6 to 12 times per day for
